Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
May 09, 2023 16:05 ET
|
Soleno Therapeutics
REDWOOD CITY, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment...
Soleno Therapeutics Completes Enrollment in Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome
May 03, 2023 16:05 ET
|
Soleno Therapeutics
Top-line data expected in Q3 2023 and has the potential to support an NDA submission for DCCR in Prader Willi Syndrome Enrollment completion satisfies closing condition on December 2022 Securities...
Soleno Therapeutics to Participate in the Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Days
March 28, 2023 08:00 ET
|
Soleno Therapeutics
REDWOOD CITY, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results
March 21, 2023 16:05 ET
|
Soleno Therapeutics
REDWOOD CITY, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment...
Soleno Therapeutics to Participate in the Oppenheimer 33rd Annual Healthcare Conference
March 07, 2023 08:00 ET
|
Soleno Therapeutics
REDWOOD CITY, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Previously Completed Phase 3 Trial of DCCR for Treatment of Prader-Willi Syndrome
January 26, 2023 08:00 ET
|
Soleno Therapeutics
REDWOOD CITY, Calif., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
Soleno Therapeutics Announces Financing Commitment for up to $60 Million
December 19, 2022 08:00 ET
|
Soleno Therapeutics
Funding from three leading healthcare investors, with Vivo Capital joining existing investors Nantahala Capital and Abingworth $10 million capital infusion at closing and $15 million upon positive...
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
November 09, 2022 16:05 ET
|
Soleno Therapeutics
REDWOOD CITY, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
Soleno Therapeutics Announces Initiation of Randomized Withdrawal Study of DCCR for the Treatment of Prader-Willi Syndrome
October 03, 2022 08:00 ET
|
Soleno Therapeutics
REDWOOD CITY, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno or the Company) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics...
Soleno Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
September 06, 2022 08:00 ET
|
Soleno Therapeutics
REDWOOD CITY, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...